ResMed Inc. Announces Results for the Second Quarter of Fiscal Year 2025Note: A webcast of ResMed’s conference call will be available at 4:30 p.m. ET today at http://investor.resmed.com
ResMed to Report Second Quarter Fiscal 2025 Earnings on January 30, 2025SAN DIEGO, Jan. 09, 2025 (GLOBE NEWSWIRE) -- ResMed (NYSE: RMD, ASX: RMD) today announced it plans to release financial and operational results for the second quarter of fiscal year 2025 on Thursday, January 30, 2025, after the New York Stock Exchange closes. Following the release, ResMed management will host a webcast to discuss the results. Other forward-looking and material information may also be discussed during the webcast.
ResMed Announces Participation in the 43rd Annual J.P. Morgan Healthcare ConferenceSAN DIEGO, Jan. 06, 2025 (GLOBE NEWSWIRE) -- ResMed (NYSE: RMD, ASX: RMD) today announced Mick Farrell, chairman and chief executive officer, and Dr. Carlos Nunez, chief medical officer, will present at the 43rd Annual J.P. Morgan Healthcare Conference on Monday, January 13, 2025, beginning at approximately 3:00 p.m. (Pacific Standard Time) in San Francisco, CA.
ResMed Announces Participation in the UBS Global Healthcare ConferenceSAN DIEGO, Nov. 05, 2024 (GLOBE NEWSWIRE) -- ResMed (NYSE: RMD, ASX: RMD) today announced Mick Farrell, Chairman and Chief Executive Officer, and Dr. Carlos Nunez, Chief Medical Officer, will participate in a fireside chat at the UBS Global Healthcare Conference on Tuesday, November 12, 2024, beginning at approximately 3:30 p.m. (Pacific Standard Time) at the Terranea Resort Hotel in Rancho Palos Verdes, CA.
ResMed Inc. Announces Results for the First Quarter of Fiscal Year 2025Note: A webcast of ResMed’s conference call will be available at 4:30 p.m. ET today at http://investor.resmed.com
ResMed to Report First Quarter Fiscal 2025 Earnings on October 24, 2024SAN DIEGO, Oct. 03, 2024 (GLOBE NEWSWIRE) -- ResMed (NYSE: RMD, ASX: RMD) today announced it plans to release financial and operational results for the first quarter of fiscal year 2025 on Thursday, October 24, 2024, after the New York Stock Exchange closes. Following the release, ResMed management will host a webcast to discuss the results. Other forward-looking and material information may also be discussed during the webcast.
ResMed Unveils 2030 Strategy to Drive Growth, Profitability, and Shareholder ReturnsNEW YORK and SAN DIEGO, Sept. 30, 2024 (GLOBE NEWSWIRE) -- ResMed (NYSE: RMD, ASX: RMD) today unveiled its 2030 Strategy to drive growth, profitability, and shareholder returns at an Investor Day in New York City. ResMed also announced its five-year revenue and earnings growth outlook, reflecting ResMed’s plans to accelerate product and technology innovation, operational excellence, commercial execution, and financial strength. Driven by the new strategy, ResMed expects to help more than 500 million people worldwide achieve their full health potential in 2030.
UPDATE -- ResMed Unveils New Collection of Digital and Personalized Solutions designed to Improve Sleep HealthSAN DIEGO, Sept. 30, 2024 (GLOBE NEWSWIRE) -- ResMed (NYSE: RMD, ASX: RMD), the world’s leading health technology company focused on sleep, breathing, and care delivered in the home, today announced new patient-centric products designed to enhance the therapy journey for sleep apnea patients. These innovations integrate with digital wearable devices and generative artificial intelligence designed to deliver a more personalized sleep health experience and improve overall health.
ResMed Unveils New Collection of Digital and Personalized Solutions designed to Improve Sleep HealthSAN DIEGO, Sept. 30, 2024 (GLOBE NEWSWIRE) -- ResMed (NYSE: RMD, ASX: RMD), the world’s leading health technology company focused on sleep, breathing, and care delivered in the home, today announced new patient-centric products designed to enhance the therapy journey for sleep apnea patients. These innovations integrate with digital wearable devices and generative artificial intelligence designed to deliver a more personalized sleep health experience and improve overall health.
ResMed to Host Its 2024 Investor Day on September 30, 2024, at the New York Stock ExchangeSAN DIEGO, Sept. 10, 2024 (GLOBE NEWSWIRE) -- ResMed (NYSE: RMD, ASX: RMD) will host an investor day on Monday, September 30, 2024, beginning at approximately 1:00 p.m. (Eastern Daylight Time). As previously announced, the event will be held at the New York Stock Exchange in New York City and simultaneously webcast online.
Vaping Expected to Increase COPD Health and Economic Burden by 2050New ResMed-supported research presented at ERS 2024 projects future Chronic Obstructive Pulmonary Disease (COPD) burden in Western Europe, accounting for increased air pollution, tobacco smoking, and vaping, with Non-Invasive Ventilation (NIV) enhancing survival rates.
ResMed Announces Participation in the Morgan Stanley 22nd Annual Global Healthcare ConferenceSAN DIEGO, Aug. 28, 2024 (GLOBE NEWSWIRE) -- ResMed (NYSE: RMD, ASX: RMD) today announced Mick Farrell, Chairman and Chief Executive Officer, and Dr. Carlos Nunez, Chief Medical Officer, will participate in a fireside chat at the Morgan Stanley 22nd Annual Global Healthcare Conference on Wednesday, September 4, 2024, beginning at approximately 10:00 a.m. (Eastern Daylight Time) at the New York Marriott Marquis in New York, NY.
ResMed Expands its Board of Directors and Appoints Healthcare Executive and Seasoned Finance Leader Christopher DelOrefice to its BoardSAN DIEGO, Aug. 15, 2024 (GLOBE NEWSWIRE) -- ResMed (NYSE: RMD, ASX: RMD) today announced it has expanded the size of its board of directors to 11 and has elected Christopher DelOrefice to the board, effective immediately. Mr. DelOrefice was appointed during ResMed’s regularly scheduled board meeting on August 15, 2024, and will stand for re-election with the rest of ResMed’s directors at its annual meeting on November 21, 2024. Mr. DelOrefice has also been appointed as a member of ResMed’s board audit committee.
ResMed Inc. Announces Results for the Fourth Quarter of Fiscal Year 2024Note: A webcast of ResMed’s conference call will be available at 4:30 p.m. ET today at http://investor.resmed.com
ResMed to Report Fourth Quarter Fiscal 2024 Earnings on August 1, 2024SAN DIEGO, July 03, 2024 (GLOBE NEWSWIRE) -- ResMed (NYSE: RMD, ASX: RMD) today announced it plans to release financial and operational results for the fourth quarter of fiscal year 2024 on Thursday, August 1, 2024, after the New York Stock Exchange closes. Following the release, ResMed management will host a webcast to discuss the results. Other forward-looking and material information may also be discussed during the webcast.
Eli Lilly Stock Up: GLP-1 Zepbound Targets Sleep Apnea MarketGlobal pharmaceutical giant Eli Lilly & Co. (
NYSELLY) has made headlines with its leading GLP-1 weight loss drugs, Mounjaro and Zepbound.
PAP Therapy Reduces Hospitalizations by 31% and ER Visits by 23% for People with Obstructive Sleep Apnea and Comorbid InsomniaResMed studies presented at SLEEP 2024 also revealed a 17% prevalence of insomnia among adults in North America, Latin America, and the Caribbean, and a higher rate of depression in women with OSA
MatrixCare Joins Health Gorilla’s Qualified Health Information Network (QHIN) to Enhance Patient Data AccessThe alliance with Health Gorilla will provide MatrixCare customers with more than 220 million patient records to streamline workflows and improve patient outcomes.
ResMed Announces Participation in the RBCCM Global Healthcare ConferenceSAN DIEGO, May 07, 2024 (GLOBE NEWSWIRE) -- ResMed (NYSE: RMD, ASX: RMD) today announced Dr. Carlos Nunez, Chief Medical Officer, and Amy Wakeham, Chief Investor Relations Officer, will participate in a fireside chat at the 2024 RBCCM Global Healthcare Conference on Tuesday, May 14, 2024, beginning at approximately 4:05 p.m. (Eastern Daylight Time) at the InterContinental New York Barclay, in New York, NY.
ResMed Inc. Announces Results for the Third Quarter of Fiscal Year 2024Note: A webcast of ResMed’s conference call will be available at 4:30 p.m. ET today at http://investor.resmed.com
ResMed to Report Third Quarter Fiscal 2024 Earnings on April 25, 2024SAN DIEGO, April 04, 2024 (GLOBE NEWSWIRE) -- ResMed (NYSE: RMD, ASX: RMD) today announced it plans to release financial and operational results for the third quarter of fiscal year 2024 on Thursday, April 25, 2024, after the New York Stock Exchange closes. Following the release, ResMed management will host a webcast to discuss the results. Other forward-looking and material information may also be discussed during the webcast.
